NeurologyOnline.net

Neurology Xagena

Uric acid may lessen women’s disability after stroke, according to new research published in Stroke, journal of American Heart Association ( AHA ). High levels of Uric acid can lead to kidney ston ...


Researchers have analyzed the evolution of non-motor symptoms and patients’ and neurologists’ clinical global impression ( CGI ) in advanced Parkinson's disease patients treated with Levodopa–Carbidop ...


A study has compared the effectiveness ( percentage of change in daily ON, OFF and dyskinesia times ) and tolerability of Levodopa-Carbidopa intestinal gel ( LCIG; Duodopa; Duopa ) in patients with Pa ...


The aim of a study was to compare the safety and efficacy of Botulinum toxin type-A ( BTX-A ) versus anticholinergic therapy as Biperiden HCl in the treatment of cervical dystonia patients. After f ...


Pooling of efficacy data across studies can provide a more precise estimate of overall treatment effect, treatment effect for endpoints measured infrequently, and variation of effect across subgroups ...


Researchers have evaluated the efficacy and the safety of a prolonged release oral formulation of Oxycodone hydrochloride combined with Naloxone hydrochloride dehydrate, in a fixed ratio of 2:1 ( OXN ...


A study has compared baseline characteristics between patients with advanced Parkinson's disease who continued with Levodopa-Carbidopa intestinal gel [ LCIG; Duodopa; Duopa ] ( contLCIG ) and patients ...


Levodopa-Carbidopa intestinal gel ( LCIG ) was evaluated for the treatment of dyskinesia in a subgroup of advanced Parkinson’s disease ( PD ) patients with relevant dyskinesia. Oral Levodopa therap ...


Biotin, used at high dose, has some impact on disease progression and permanent disability in patients with progressive multiple sclerosis. Overall, 21/23 patients ( 91.3% ) exhibited some qualitative ...


No drug has been found to have any impact on progressive multiple sclerosis ( MS ). Biotin is a vitamin acting as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acids ...


In a study published in The Journal of Experimental Medicine, researchers, at the Wihuri Research Institute and the University of Helsinki, have reported a surprising finding that challenges current a ...


Cardiovascular disease is a recognized contributor to the pathogenesis of Alzheimer's disease. Heart failure is a cardiovascular subtype that can be used to model the contribution of cardiovascular di ...


Positive results from the pivotal phase III clinical trial, MS-SPI were presented at the American Academy of Neurology Annual Meeting. The study demonstrated evidence of the efficacy and safety of M ...


Cysteine could potentially lower the risk of stroke through antihypertensive and antioxidant effects. A study has evaluated the hypothesis that cysteine intake is inversely associated with stroke in ...


Twenty-three patients aged from 26 to 75 years ( mean=52.8 years ) were treated with high doses of Biotin from 2 to 36 months ( mean treatment׳s duration=9.2 months ). Fourteen patients suffered fro ...


A research presented at the International Stroke Conference ( ISC ) and published in The New England Journal of Medicine ( NEJM ) found that the addition of the Solitaire Device stent thrombectomy pro ...


Data from a pre-specified interim analysis of PRIME, the phase 1b study of Aducanumab ( BIIB037 ) were presented at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Relate ...


Increasing evidences link T helper 17 ( Th17 ) cells with multiple sclerosis ( MS ). In this context, interleukin-22 ( IL-22 ), a Th17-linked cytokine, has been implicated in blood brain barrier break ...


In 85% of cases, multiple sclerosis ( MS ) initially evolves through relapses that resolve completely or incompletely ( relapsing-remitting multiple sclerosis or RRMS ). However, in about 50% of cas ...


Teva Pharmaceutical has announced the successful completion of its Phase IIb migraine prevention program with positive top-line results from a Phase IIb study evaluating the efficacy, safety and toler ...


Hemicrania continua is a strictly unilateral, continuous headache, typically mild to moderate in severity, with severe exacerbations commonly accompanied by cranial autonomic features and migrainous s ...


The purpose of a study was to monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during Topiramate ( Topamax ) treatment. Patients with migraine ...


Hemiplegic migraine is a particularly severe form of the disease that often evolves to a debilitating chronic illness that is resistant to commonly available therapies. Peripheral neurostimulation h ...


The FDA ( Food and Drug Administration ) has approved Watchman Left Atrial Appendage Closure Device. The Watchman Device offers a new stroke risk reduction option for high-risk patients with non-valvu ...


The FDA ( Food and Drug Administration ) has cleared for marketing the ENROUTE Transcarotid Neuroprotection System ( ENROUTE TNS ), for use during a minimally invasive procedure to restore normal bloo ...


In patients with Alzheimer's disease ( AD ), the relationship between cognitive and functional progression is not fully understood; however, functional decline has been postulated to follow cognitive ...


The Food and Drug Administration ( FDA ) has approved Duopa ( Carbidopa and Levodopa ) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. Duopa is ...


A 7-year experience assessing safety and outcomes of Levodopa / Carbidopa intestinal gel infusion ( LCIG ) in 59 advanced Parkinson disease ( PD ) patients presenting motor fluctuations and severe dys ...


The initial headline conclusions from DIAS-3, the first of two phase III clinical trials of Desmoteplase for the treatment of adult patients with acute ischaemic stroke, were announced. The study d ...


Previous therapeutic strategies for multiple sclerosis ( MS ) include the non-selective suppression of systemic immunity ( immunosuppressive agents, such as glucocorticoids, Mitoxantrone and Azathiopr ...


Natalizumab ( Tysabri ) has shown its efficacy in reducing multiple sclerosis ( MS ) relapses and progression of disability; however, it has been associated with an increased risk of developing progre ...


Literature has suggested that changes in brain flow circulation occur in patients with multiple sclerosis. In a study, digital subtraction angiography ( DSA ) was used to measure the absolute cerebral ...


In a 6-month double-blind, placebo-controlled study of Parkinson's disease patients with motor fluctuations, Safinamide ( Xadago ) 50 and 100 mg/die significantly increased ON-time without increasing ...


Previous reports indicate an association between Epstein-Barr virus ( EBV ) antibody levels and multiple sclerosis ( MS ) disease activity, but the results have been conflicting. The objective of a ...


Psychiatric disorders are known to be prevalent in multiple sclerosis ( MS ). The objective of this paper was to study comorbidity between multiple sclerosis and bipolar disorder, schizophrenia and de ...


Statin use during hospitalization is associated with improved survival and a better discharge disposition among patients with ischemic stroke. It is unclear whether inpatient statin use has a similar ...


The benefit of statins in patients with acute aneurysmal subarachnoid haemorrhage is unclear. A study aimed to determine whether Simvastatin ( Zocor ) 40 mg could improve the long-term outcome in pati ...


Previous reports have indicated an association between Epstein-Barr virus ( EBV ) antibody levels and multiple sclerosis ( MS ) disease activity, but the results have been conflicting. The objectiv ...


Subcutaneous Pegylated interferon ( Peginterferon ) beta-1a ( Plegridy ) has been developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line ...


It has been demonstrated that the internal jugular vein may exhibit abnormalities classified as truncular venous malformations ( TVMs ). The investigation of possible morphological and biochemical ano ...


Traumatic brain injury ( TBI ) is a major cause of death and disability worldwide. Progesterone has been shown to improve neurologic outcome in multiple experimental models and two early-phase trials ...


Levodopa is effective for the motor symptoms of Parkinson's disease ( PD ), but is associated with motor fluctuations and dyskinesia. Many patients require add-on therapy to improve motor fluctuations ...


The baseline severity of cervical dystonia is shown in short segments, along with outcomes after 6 months of pallidal neurostimulation in three study participants. Cervical dystonia is managed mainly ...


Patients who develop relapsing-remitting multiple sclerosis ( MS ) present with a first clinical demyelinating event. In this double-blind, multicentre, randomised, phase 3 study, ORACLE MS, researche ...


A study has evaluated the effect of slow-release ( SR ) Fampridine ( Fampyra ) on multiple outcome measures reflecting different domains, and to compare the responsiveness of the Six Spot Step Test ( ...


No available treatments slow or halt progression of multiple system atrophy, which is a rare, progressive, fatal neurological disorder. In a mouse model of multiple system atrophy, Rifampicin ( Rifadi ...


Teriflunomide ( Aubagio ) is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting multiple sclerosis. Researchers have assessed the efficacy and safety of Teriflunomi ...


Whether initial treatment for Parkinson's disease should consist of Levodopa, dopamine agonists, or monoamine oxidase type B inhibitors ( MAOBI ) is uncertain. Researchers aimed to establish which o ...


The Committee for Medicinal Products for Human Use ( CHMP ) has recommended that the European Commission approve the use of Xadago ( Safinamide ) as add-on to L-dopa alone or in combination with dopam ...


The lack of prospective trial data comparing certain multiple sclerosis therapies could be addressed with observational research. Researchers have investigated outcomes of Natalizumab ( Tysabri ) v ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati